Skip to content
ADMETatlas
peptide evidence atlas
Home
About
Home

Browse

PeptidesProductsEvidenceContext signalsDescriptors

Developability

ProfileComparator

Resources

ManualExplanationsStatisticsDownloadLicenseAbout
  1. Home
  2. Peptides
  3. Octreotide
Peptide·plain sequence-like

Octreotide

ATLPC0025642

FCFWKTCT

Routes
Compare in workbenchDownload releaseAPI JSON
  • Length
    8 aa
  • Monoisotopic mass
    1034.4 Da
  • Net charge @ pH 7.4
    1.00
  • Isoelectric point
    8.23
  • GRAVY
    0.550
On this page
  • 01 Sequence & molecular identity
  • 02 Physicochemical profile
  • 03 Exposure / Absorption
  • 04 Distribution / Barrier
  • 05 Excretion / Persistence
  • 06 Evidence landscape
  • 07 Product context
  • 08 Identity & reference map
  • 09 Data access & reproducibility
Coveragecounts only · not riskATLPC0025642
  • Measurements
    60
  • Endpoints
    9
  • Domains
    3/5
  • Products
    1
  • No matrix stability evidence
  • 18 clearance measurements
  • Product-level review pending
  • 2 liability motifs
Jump to domain

Open the matching evidence section below

All evidence index · 60
Exposure / Absorption
20 measurements
Distribution / Barrier
22 measurements
Metabolic & Proteolytic Stability
No evidence
Excretion / Persistence
18 measurements
Toxicity / Safety
No evidence
01

Sequence & molecular identity

1 forms

Reviewed sequence, peptidoform forms, chemical representation, 3D references, and covalent topology used to interpret this peptide identity.

Sequence & peptidoform

·
Identity summaryCanonical sequence only
Identity status
Canonical sequence only
Residues
8
Peptidoform features
0
Documented molecular forms
1
Representations
2
Documented molecular forms1 form linked to this peptide identity
FormTopologyModificationsConnectionsRepresentationsMeasurements
ATLPF0027909———Notation only4
Residue view
Residue display
8 residues
F1C2F3W4K5T6C7T8
Side-chain classNonpolarPolarBasic (+)Acidic (−)Modified

Soft tints mark standard side-chain classes for scanning. Primary emphasis is reserved for reported modifications, termini, secondary-structure tracks, and topology links.

Peptidoform features

Features are shown only when a reported notation or topology record supports them.

No terminal modification, residue-level marker, disulfide, staple, coordination, or other topology signal is currently available.

Structure & chemistry

·
Chemical representationsequence / HELM only
Representation class

How the current release can interpret this identity chemically.

plain sequence-like
Parent-residue sequence

Residue string used for positional interpretation when available.

FCFWKTCT
HELM

Polymer notation for modified peptide representation when available.

Not available
SMILES

Chemical graph string used for atom-level 2D depiction when available.

Not available
No atom-level graph

A reviewed SMILES is required before a 2D molecular depiction can be shown. Sequence and HELM remain useful for identity interpretation, but they do not replace a chemical graph.

3D structure referencesnone attached
3D structure not available

A 3D structure isn't available for this peptide in the current release. Chemistry and topology fields remain available when represented by sequence, HELM, or SMILES.

Covalent topology & modificationsnone
Exact topology not established

No reviewed form-level topology or residue-level connection annotation is attached to this peptide in the current release. This is not evidence that every molecular form is linear or unmodified.

02

Physicochemical profile

4 descriptors

Computed sequence-derived descriptors and any measured physicochemical evidence such as lipophilicity. Computed values are interpretation aids, not experimental ADMET measurements.

·
Core descriptors8 aa · pI 8.2 · GRAVY 0.55
Length
8 aa
Monoisotopic mass
1034.44 Da
Average mass
1035.24 Da
Net charge at pH 7.4
1.00
Estimated pI
8.23
GRAVY
0.550
KD-positive residues
50.0%
Aromatic residues
37.5%
Developability interpretation
Ionization context
pH 7.4 close to pI
Hydrophobicity balance
Leans hydrophobic
Amphipathic moment (μH)
0.71
Computation boundary
Standard-sequence only
Charge & residue composition
pH charge context

Modeled net charge across common formulation and assay pH checkpoints.

pH 2
1.98
pH 5
1.04
pH 6
1.00
pH 7.4
0.79
pH 9
-1.25
pH 12
-2.94
Residue-class composition

Grouped composition is often more interpretable than a long amino-acid list.

Basic (K,R,H)
1 · 12.5%
Polar uncharged (N,Q,S,T)
2 · 25.0%
Aromatic (F,W,Y)
3 · 37.5%
Conformational / sulfur (G,P,C)
2 · 25.0%
Top residues
C225.0%F225.0%T225.0%K112.5%W112.5%
Hydropathy & amphipathic windows
Hydropathy windows

Seven-residue sliding windows expose local patches hidden by whole-sequence GRAVY.

Most hydrophobic window
1-7
FCFWKTC
GRAVY 0.729
Most hydrophilic window
2-8
CFWKTCT
GRAVY 0.229
2 local hydropathy windows scanned. A local patch is context for solubility, adsorption, and membrane interaction review, not a standalone endpoint.
Amphipathic-window scan

Top alpha-helix hydrophobic-moment windows across 12, 15, 18, and 21 residues.

Sequence is shorter than the local amphipathic-window sizes used here.
Sequence-liability cues
Sequence-liability notes

Motifs are review prompts for formulation or CMC interpretation; they are not degradation predictions.

Oxidation-sensitive residues
W, C · pos 2, 4, 7
Met, Trp, and Cys residues can merit formulation review for oxidation or covalent-state sensitivity.
Cys covalent complexity
C · pos 2, 7
Multiple cysteines can indicate disulfide or free-thiol interpretation requirements.
Alpha-helix amphipathic projection
Helical wheel · Edmundson projection
μH = 0.71100°/residue · 8 aa
μH1: F (Phe) · Aromatic · K-D 2.8F12: C (Cys) · Special · K-D 2.5C23: F (Phe) · Aromatic · K-D 2.8F34: W (Trp) · Aromatic · K-D -0.9W45: K (Lys) · Basic + · K-D -3.9K56: T (Thr) · Polar · K-D -0.7T67: C (Cys) · Special · K-D 2.5C78: T (Thr) · Polar · K-D -0.7T8
Hydrophobic moment0.71
Mean K-D hydropathy0.55
Approx. net charge+1
Projection angle100° / residue
The pale sector marks the direction of the hydrophobic face inferred from μH. This is a projection assumption, not a measured fold.
HydrophobicAromaticPolarBasic +Acidic −Specialhydrophobic faceμH arrow → hydrophobic face

The projection assumes an α-helix conformation; a long μH arrow indicates an amphipathic helix, common in antimicrobial peptides.

Method notes

Charge model: side-chain pKa D 3.9, E 4.1, C 8.5, Y 10.1, H 6.5, K 10.8, R 12.5 with EMBOSS termini. pI is estimated by binary search on modeled net charge. Hydropathy uses Kyte-Doolittle values; hydrophobic moment follows the Eisenberg alpha-helix vector-sum convention. When the basis is a parent-residue sequence, modified chemistry is intentionally not inferred.

Computed developability descriptors

Deterministic descriptors computed from the reviewed sequence or chemical structure (RDKit), each anchored to a literature method. These are computed estimates for developability interpretation — not experimental measurements — and are validated against independent reference implementations.

Sequence-derived

Computed from the standard parent-residue sequence; protein-origin metrics defined at any length.

Aliphatic index
0.00
Instability index
49.5

Above 40 — predicted unstable in vitro.

Boman index
-0.02 kcal/mol
Molar extinction coefficient (280 nm)
5,500 M⁻¹·cm⁻¹

A280 (1 g/L) ≈ 5.31 · 5,625 M⁻¹·cm⁻¹ with 1 disulfide

Structure-derived descriptors are not shown because this identity has no resolved chemical structure (SMILES). This is a known coverage gap for disulfide-rich and unresolved peptidoforms, not a computation error.

03

Exposure / Absorption

20 records

What evidence describes systemic exposure or absorption?

Evidence records
20
Complete canonical measurements and observations attached to this domain.
Endpoint scope
4
Formal ADMET endpoints represented for this peptide.
Matched-context in preview
0
Quantitative results that may be analysed only with scientifically compatible records.
Reported results in preview
7
Qualitative, narrative, or review-first results interpreted in their source context.
Endpoints in scopeBioavailabilityTmaxCmaxAUC
Loading 20 Exposure / Absorption records…
04

Distribution / Barrier

22 records

What is known about distribution, binding, permeability, or barrier crossing?

Evidence records
22
Complete canonical measurements and observations attached to this domain.
Endpoint scope
3
Formal ADMET endpoints represented for this peptide.
Matched-context in preview
0
Quantitative results that may be analysed only with scientifically compatible records.
Reported results in preview
4
Qualitative, narrative, or review-first results interpreted in their source context.
Endpoints in scopePlasma protein bindingBBB penetrationVd
Loading 22 Distribution / Barrier records…
Barrier and permeability assay context

PAMPA, Caco-2, MDCK/RRCK, and BBB findings are assay/model contexts under Distribution / Barrier. They should not be read as interchangeable measurements.

PAMPA
0

artificial membrane

Caco-2
0

cell monolayer

MDCK
0

cell monolayer

RRCK
0

cell monolayer

BBB
3

barrier evidence

05

Excretion / Persistence

18 records

What evidence describes clearance or persistence?

Evidence records
18
Complete canonical measurements and observations attached to this domain.
Endpoint scope
2
Formal ADMET endpoints represented for this peptide.
Matched-context in preview
3
Quantitative results that may be analysed only with scientifically compatible records.
Reported results in preview
3
Qualitative, narrative, or review-first results interpreted in their source context.
Endpoints in scopeHalf LifeClearance
Loading 18 Excretion / Persistence records…
06

Evidence landscape

60 records

Cross-domain evidence distribution and measurement-level detail. 20 of 60 evidence records are included in the profile preview; the full index is loaded below.

Loading 60 measurements…
07

Product context

1 products

Product-level route, label, and clinical context that frames peptide-level evidence. A peptide-level summary only; product pages keep the full drilldown.

·
Summary1 linked product
Linked products
1
Label context
1
Clinical trials
42
Safety label cues
None
Linked products1 shown

Octreotide

SANDOSTATINSANDOSTATIN LAR
Peptide-product match
Unique peptide match
Route / product class
Not resolved in this release
Clinical context
42 trial records · 17 exact intervention matches · 15 with results · latest 2026-03-19
Label safety context
Label linked
View product
08

Identity & reference map

60 sources

Reference-level support for checking reported names, sequence notation, and peptide identity agreement.

·
Summary11 reference groups
Identity type
canonical sequence
Reported notation
2
Reference groups
11
Measurements
60
ATL peptide ID
ATLPC0025642
Identity concordance
Identity concordance
Exact reported notation

Reported sequence string matches the current peptide notation.

12 / 60
Parent-residue compatible

Reported notation differs, but resolves to the same parent-residue display.

0 / 60
Different notation

Reported notation does not resolve to the current display sequence.

2 / 60
Source sequence not captured

No source-specific sequence was captured for comparison; this is not interpreted as agreement or disagreement.

46 / 60
Reported sequence notation
Exact12 references
fCFwKTCT
Different2 references
fCFwKTCX
Current identity
FCFWKTCT
Reported names
brainpeps_observation_v2_5_3_56_0f7311313539c884e1dfbrainpeps_observation_v2_5_3_56_4a4e1f5e20ead0602396brainpeps_observation_v2_5_3_56_4d1c5970d3090acd6684brainpeps_observation_v2_5_3_56_6a44f489f57adf9598fcbrainpeps_observation_v2_5_3_56_6b0a5bb87e59ff745569brainpeps_observation_v2_5_3_56_af1b4b2b8c92245c1303brainpeps_observation_v2_5_3_56_bab5b2ebabb25dd78c5dbrainpeps_observation_v2_5_3_73_66788ae84f2cfc3b7a05brainpeps_observation_v2_5_3_73_71ed04d16febfe44812dbrainpeps_observation_v2_5_3_73_aae8d2b4287c8524758bbrainpeps_observation_v2_5_3_73_bd32e7d5c68ce8194a48brainpeps_observation_v2_5_3_73_f3997434d711ac239b21
Reference map11 reference groups
Reference map

Grouped by reference link, with endpoint scope and reported identity kept visible.

ReferenceSupportsReported identityRecords
Reference
Open
Identity only
No reported alias
25 identity
0 evidence
Reference
Open
ExposurePersistence
Area Under Curve, Clearance, Max Concentration, Time To Max Concentration
No reported alias
12 identity
7 evidence
Source record
Open
Distribution
Blood Brain Barrier Penetration
brainpeps_observation_v2_5_3_56_0f7311313539c884e1df, brainpeps_observation_v2_5_3_56_4a4e1f5e20ead0602396, brainpeps_observation_v2_5_3_56_4d1c5970d3090acd6684 +9 more
fCFwKTCTexact
12 identity
2 evidence
Reference
Open
Persistence
Half Life
No reported alias
2 identity
2 evidence
Reference
Open
Persistence
Half Life
No reported alias
2 identity
2 evidence
Source record
Open
DistributionExposure
Bioavailability, Plasma Protein Binding
No reported alias
fCFwKTCXdifferent
2 identity
2 evidence
Reference
Open
Persistence
Half Life
No reported alias
1 identity
1 evidence
Reference
Open
Persistence
Half Life
No reported alias
1 identity
1 evidence
Reference
Open
Persistence
Half Life
No reported alias
1 identity
1 evidence
Source record
Open
Distribution
Blood Brain Barrier Penetration
No reported alias
1 identity
1 evidence
1–10 / 11
09

Data access & reproducibility

Stable record access, analysis-ready files, and scripted retrieval for reproducing this profile view.

·
Record scopePublic release
ATL peptide ID
ATLPC0025642
Identity type
canonical sequence
ADMET endpoints
9
Evidence records
60
Reference groups
11
Release view
Public release
Data access

Structured peptide profile

JSON

Peptide-specific profile used by this page, including identity and evidence context.

Open JSON

Peptide catalogue

TSV

Complete frozen peptide table. Filter the ATL peptide ID column locally to isolate this record.

Download catalogue

Measurement catalogue

TSV

Complete frozen measurement table. Join or filter by ATL peptide ID for peptide-level analysis.

Download measurements
Programmatic access

The request returns the same structured peptide record used by this profile. The tabular downloads are complete frozen release tables and should be filtered locally by ATL peptide ID.

Open endpoint
GET /api/v1/peptides/ATLPC0025642
open
curl -sS 'https://admetatlas.scbdd.com/api/v1/peptides/ATLPC0025642' \
  -H 'accept: application/json' \
  -H 'X-Visibility: public_release'
ADMETatlas
peptide evidence atlas

ADMETatlas is an open, curated atlas of ADMET evidence for therapeutic peptides — spanning developability, membrane permeability and blood–brain-barrier transport, immune-recognition context, and approved-product context. Every measurement stays linked to its original source, with stable identifiers and transparent curation, so results can be traced, cited, and reproduced.

Browse
PeptidesProductsEvidenceContext signalsDescriptors
Resource
DevelopabilityComparatorManualExplanationsStatisticsDownloadAbout
Stack
  • RDKit
  • Mol*
  • Python
  • FastAPI
  • PostgreSQL
  • Next.js
  • React
  • TypeScript
  • Tailwind CSS
  • Apache ECharts
© 2026 ADMETatlas, an academic peptide ADMET evidence atlas.